Please assess the completion status of the following clinical trial:

Trial Title: Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly histologic diagnosis of nasopharyngeal carcinoma(WHO II/III)~* Clinical stage III\~IVb(UICC 7th)~* Meet at least one factor below :1 primary tumor SUVmax\>10 in 18F-FDG PET/CT;2 primary tumor volume\>30cm3;3 mutiple metastatic cervical lymph node with at least one's short diameter\>4cm; 4 T4N2M0; 5 T1-4N3M0;6 EBV-DNA\>2×10E4 copy/l~* Range from 18～70 years old~* WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L~* ALT or AST \< 2.5×ULN、bilirubin \< 1.5×ULN~* OSerum creatinine \< 1.5×ULN~Exclusion Criteria:~* Central nervous system metastases~* Suitable for local treatment~* Uncontrolled seizure disorder or other serious neurologic disease~* Clinically significant cardiac or respiratory disease~* Drug or alcohol addition~* Do not have full capacity for civil acts~* Severe complication, active infection~* Concurrent immunotherapy or hormone therapy for other diseases~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Concurrent chemoradiation + adjuvant chemotherapy (Type: EXPERIMENTAL): IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy
- Concurrent chemoradiation (Type: ACTIVE_COMPARATOR): IMRT combine with cisplatin concurrent chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).